Depakote ER Promotion Cannot Claim Bioequivalence With Original Drug – FDA
Executive Summary
FDA is discouraging Abbott from comparing its extended-release and delayed-release versions of its manic depression treatment Depakote in promotional materials, a move that undercuts the central tenet of most industry ever-greening strategies
You may also be interested in...
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Neurocrine Inks $575 Mil. Deal With Abbott To Develop and Sell Gynecologic, Elagolix
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.